Cancer Research Technology
Log in Register
Menu

ZR-75-1 estrogen independent breast cancer cell line panel (2)
NEW

Info

Catalogue Number 154645
Antigen/Gene or Protein Targets BCAR1, BCAR3, AKT1, AKT2, BCAR4, GRB7, EGFR, HRAS, PDGFRA, PDGFRB, RAF1
Parental Line ZR-75-1
Host Human
Tissue Breast
Disease Keywords Mammary ductal carcinoma, estrogen independent
Model Cancer Model
Relevance Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied different genetic screens to identify the main genes conferring estrogen independence.

Out of 15 candidate BCAR genes, several including BCAR1, BCAR3, AKT1, AKT2, BCAR4, GRB7, EGFR, HRAS, PDGFRA, PDGFRB and RAF1 were shown to directly underlie estrogen independence by transfection into the ZR-75-1 breast cancer cell line resulting in a panel of 16 cell lines (Cat No 154621-154635, 154642)

These cell lines are a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity.
Production Details Full length cDNA of the relevant gene was introduced in the estrogen-dependent ZR-75-1 cell line by transfection with lipofectamine
Conditional No
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17β-estradiol
Notes These cell lines are resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells.
As a consequence of the presence of a BCAR genes, these cells can also proliferate in the absence of estrogen or even in the presence of anti-estrogens.

References

There are 7 reference entries for this reagent.

View All References

References: 7 entries

Godinho et al. 2011. J Cell Physiol. 226(7):1741-9. PMID: 21506106.

van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.

van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.

Meijer et al. 2006. Mol Cancer Res. 4(6):379-86. PMID: 16778085.

Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.

van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.

van Agthoven et al. 1992. Cancer Res. 52(18):5082-8. PMID: 1516065.


Add a reference

References: 7 entries

Godinho et al. 2011. J Cell Physiol. 226(7):1741-9. PMID: 21506106.

van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.

van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.

Meijer et al. 2006. Mol Cancer Res. 4(6):379-86. PMID: 16778085.

Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.

van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.

van Agthoven et al. 1992. Cancer Res. 52(18):5082-8. PMID: 1516065.


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor